Citi upgraded ProQR Therapeutics (PRQR) to Buy from Neutral with a $4 price target The firm is revisiting its thesis with shares trading nearly at cash with minimal value being attributed to lead drug AX-0810, the company’s RNA editing therapy targeting the bile acid transporter for cholestatic diseases. Given the continued stock decline post the mid-October 2024 spike, and with a potentially value-inflecting top-line readout later this year, the firm is upgrading the stock, adding that the pipeline should be worth more than roughly $50M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
Questions or Comments about the article? Write to editor@tipranks.com